Nov 26, 2007
MIV Therapeutics to Present at the BMO Capital Markets Focus on Healthcare Conference
Nov 12, 2007
MIV Therapeutics Receives India Regulatory Approval for Two Bare Metal Stents
Nov 8, 2007
New Data Show MIV Therapeutic's Vestasync Drug Eluting Stent Produces Less Fibrinoid and Equivalent Efficacy When Compared to Other Stents
Oct 23, 2007
MIV Therapeutics Announces Live Vestasync Follow-Up Case Performed at TCT Conference
Oct 22, 2007
MIV Therapeutics Announces Positive Results from First Human Study With its Vestasync Stent
Oct 16, 2007
Results of First-In-Man Study With MIVT Low Dose Polymer-Free Drug-Eluting Stent to Be Presented at TCT Conference
Jul 19, 2007
MIV Therapeutics Presents Transcript of Latest Investor Conference Call Recapping Company’s Milestone Achievements and Strategic Plans for 2007 and Beyond
Jun 11, 2007
MIV Therapeutics Names Methodist Hospital Research Cardiologist Dr. Greg Kaluza to Scientific Advisory Board
May 31, 2007
MIV Therapeutics Announces Start of Clinical Trial Marking First Ever Human Implantation of A Hydroxyapatite Coated Stent
May 25, 2007
MIV Therapeutics Appoints Internationally Renowned Cardiologist and Chief Executive Officer of Kailash Heart Institute as Clinical Advisor
May 22, 2007
MIV Therapeutics Announces Renowned Researcher to Detail Milestone Pre-Clinical Results at Prominent International Conference EuroPCR 2007
Apr 17, 2007
MIV Therapeutics Announces First Ever Revenues from Cardiovascular Products Approved for European and Other Markets
Mar 30, 2007
MIV Therapeutics Cites Growing Body of Scientific Literature Demonstrating Critical Need for Company’s Device to Prevent Stroke
Jan 8, 2007
MIV Therapeutics Executes Private Financings for $4 Million to Support Acquisitions, Development and Distribution of Next Generation Stents
